Search
Now showing items 181-190 of 214
Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG)
(1994)
In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of ...
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
(2007)
Purpose: Paclitaxel and carboplatin are frequently used in advanced ovarian cancer following cytoreductive surgery. Threshold models have been used to predict paclitaxel pharmacokinetic-pharmacodynamics, whereas the time ...
Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases
(2011)
Purpose: To study the phenomenon of positive urine cytology in patients with lung cancer in the absence of obvious urothelial metastases. Patients and methods: 150 patients with small (SCLC) and non-small cell lung cancer ...
Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary
(2012)
Cancer of unknown primary (CUP) is a heterogeneous entity, managed on the basis of "one size fits all" therapeutic concepts; insights into the molecular biology of CUP are urgently needed. We retrospectively examined the ...
A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG)
(1996)
In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bioreductive alkylating indoloquinone. The drug was ...
The effect of plasma homocysteine levels on clinical outcomes of patients with acute lung injury/acute respiratory distress syndrome
(2009)
Background: Several reports have shown that homocysteine promotes thrombosis by disturbing the procoagulant-anticoagulant balance, whereas alterations in coagulation and fibrinolysis have been suggested as important ...
Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?
(2005)
Carcinoma of unknown primary (CUP) is characterized by dismal patient survival. The outcome of patients with two favourable risk CUP subsets was studied. Eighty patients diagnosed with either midline lymph node metastases ...
Metabolic syndrome and its components as predictors of ischemic stroke in type 2 diabetic patients
(2008)
BACKGROUND AND PURPOSE - The available data regarding the association between metabolic syndrome (MS) or MS components and ischemic stroke in type 2 diabetics are limited and inconsistent. This study aimed to investigate ...
Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients
(2012)
Background: To investigate a possible role of Cefditoren, a recently marketed in Greece third-generation oral cephalosporin in urinary infections of outpatients.Methods: During a multicenter survey of Enterobacteriaceae ...
Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A prospective study
(1997)
From June 1984 to October 1995, forty seven consecutive patients (pts) with a confirmed diagnosis of diffuse malignant mesothelioma (MM) of the pleura (41) and peritoneum (6), were treated with cisplatin (CDDP) (24 pts) ...